Pompe Disease - Pipeline Review, H2 2015

Description: Pompe Disease - Pipeline Review, H2 2015

Summary

The report 'Pompe Disease - Pipeline Review, H2 2015', provides an overview of the Pompe Disease's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Pompe Disease, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Pompe Disease and special features on late-stage and discontinued projects.

The report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles/records featured in the report undergoes periodic updates following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Pompe Disease
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in the therapeutics development for Pompe Disease and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects
- A review of the Pompe Disease products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Pompe Disease pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Pompe Disease
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Pompe Disease pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Contents:

List of Tables
List of Figures
Introduction
Report Coverage
Pompe Disease Overview
Therapeutics Development
Pipeline Products for Pompe Disease - Overview
Pipeline Products for Pompe Disease - Comparative Analysis
Pompe Disease - Therapeutics under Development by Companies
Pompe Disease - Therapeutics under Investigation by Universities/Institutes
Pompe Disease - Pipeline Products Glance
Late Stage Products
Clinical Stage Products
Early Stage Products
Pompe Disease - Products under Development by Companies
Pompe Disease - Products under Investigation by Universities/Institutes
Pompe Disease - Companies Involved in Therapeutics Development
Alexion Pharmaceuticals, Inc.
Amicus Therapeutics, Inc.
Audentes Therapeutics, Inc.
BioMarin Pharmaceutical Inc.
Cortex Pharmaceuticals, Inc.
EpiVax, Inc.
Etubics Corporation
Genzyme Corporation
greenovation Biotech GmbH
Oxyrane Belgium NV
Pharming Group N.V.
Sarepta Therapeutics, Inc.
Pompe Disease - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Combination Products
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
Antisense Oligonucleotide to Activate Acid Alpha-Glucosidase for Pompe Disease - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Antisense Oligonucleotide to Activate Lysosomal Alpha-Glucosidase for Pompe Disease - Drug Profile
Product Description
Mechanism of Action
R&D Progress
AT-002 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
ATB200 + Chaperone - Drug Profile
Product Description
Mechanism of Action
R&D Progress
CX-1739 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
CX-717 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
duvoglustat hydrochloride + alglucosidase alfa - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Gene Therapy 1 to Activate Acid Alpha-Glucosidase for Pompe Disease - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Gene Therapy 2 to Activate Acid Alpha-Glucosidase for Pompe Disease - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Gene Therapy to Activate Acid Alpha-Glucosidase for Pompe Disease - Drug Profile
Product Description
Mechanism of Action
R&D Progress
GZ-402666 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
MOSS-GAA - Drug Profile
Product Description
Mechanism of Action
R&D Progress
OXY-2810 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Recombinant Enzyme to Replace Alpha Glucosidase for Pompe Disease - Drug Profile
Product Description
Mechanism of Action

R&D Progress

Recombinant Enzymes for Pompe, Fabry and Hunter Diseases - Drug Profile

Product Description

Mechanism of Action

R&D Progress

reveglucosidase alfa - Drug Profile

Product Description

Mechanism of Action

R&D Progress

Synthetic Peptides for Pompe disease - Drug Profile

Product Description

Mechanism of Action

R&D Progress

VAL-1221 - Drug Profile

Product Description

Mechanism of Action

R&D Progress

Pompe Disease - Recent Pipeline Updates

Pompe Disease - Dormant Projects

Pompe Disease - Product Development Milestones

Featured News & Press Releases

Sep 03, 2015: Valerion Therapeutics Announces Positive Results Of Non-Clinical Research Study at SSIEM Annual Symposium

May 11, 2015: Audentes Therapeutics To Present New Data On AT-002 at American Society of Gene and Cell Therapy Annual Meeting

May 04, 2015: Cortex Pharmaceuticals Announces Publication of Research Results on the Use of Ampakines CX1739 in the Treatment of Respiratory Disorders

Feb 10, 2015: Amicus Therapeutics Presents Preclinical Data on Next-Generation Pompe ERT at WORLD Symposium 2015

May 27, 2014: BioMarin Doses First Patient in Phase 3 INSPIRE Trial with BMN 701 for the Treatment of Pompe Disease

Mar 19, 2013: BioMarin Announces Results from Phase I/II Trial Of BMN-701 For Treatment Of Pompe Disease, Plans To Initiate Phase II/III Trial
Jan 04, 2013: Amicus Therapeutics Announces Positive Results From All Four Cohorts In Phase II Chaperone-enzyme Replacement Therapy Co-Administration Study For Pompe Disease

Oct 11, 2012: Amicus Therapeutics Announces Positive Pompe Program Updates

Jun 26, 2012: Amicus Announces Positive Preliminary Results From Phase II Chaperone-Enzyme Replacement Therapy Co-Administration Study For Pompe Disease

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

Number of Products under Development for Pompe Disease, H2 2015
Number of Products under Development for Pompe Disease - Comparative Analysis, H2 2015
Number of Products under Development by Companies, H2 2015
Number of Products under Investigation by Universities/Institutes, H2 2015
Comparative Analysis by Late Stage Development, H2 2015
Comparative Analysis by Clinical Stage Development, H2 2015
Comparative Analysis by Early Stage Development, H2 2015
Products under Development by Companies, H2 2015
Products under Investigation by Universities/Institutes, H2 2015
Pompe Disease - Pipeline by Alexion Pharmaceuticals, Inc., H2 2015
Pompe Disease - Pipeline by Amicus Therapeutics, Inc., H2 2015
Pompe Disease - Pipeline by Audentes Therapeutics, Inc., H2 2015
Pompe Disease - Pipeline by BioMarin Pharmaceutical Inc., H2 2015
Pompe Disease - Pipeline by Cortex Pharmaceuticals, Inc., H2 2015
Pompe Disease - Pipeline by EpiVax, Inc., H2 2015
Pompe Disease - Pipeline by Etubics Corporation, H2 2015
Pompe Disease - Pipeline by Genzyme Corporation, H2 2015
Pompe Disease - Pipeline by greenovation Biotech GmbH, H2 2015
Pompe Disease - Pipeline by Oxyrane Belgium NV, H2 2015
Pompe Disease - Pipeline by Pharming Group N.V., H2 2015
Pompe Disease - Pipeline by Sarepta Therapeutics, Inc., H2 2015
Assessment by Monotherapy Products, H2 2015
Assessment by Combination Products, H2 2015
Number of Products by Stage and Target, H2 2015
Number of Products by Stage and Mechanism of Action, H2 2015
Number of Products by Stage and Route of Administration, H2 2015
Number of Products by Stage and Molecule Type, H2 2015
Pompe Disease Therapeutics - Recent Pipeline Updates, H2 2015
Pompe Disease - Dormant Projects, H2 2015

List of Figures

Number of Products under Development for Pompe Disease, H2 2015
Number of Products under Development for Pompe Disease - Comparative Analysis, H2 2015
Number of Products under Development by Companies, H2 2015
Comparative Analysis by Clinical Stage Development, H2 2015
Comparative Analysis by Early Stage Products, H2 2015
Assessment by Monotherapy Products, H2 2015
Assessment by Combination Products, H2 2015
Number of Products by Targets, H2 2015
Number of Products by Stage and Targets, H2 2015
Number of Products by Mechanism of Actions, H2 2015
Number of Products by Stage and Mechanism of Actions, H2 2015
Number of Products by Routes of Administration, H2 2015
Number of Products by Stage and Routes of Administration, H2 2015
Number of Products by Molecule Types, H2 2015
Number of Products by Stage and Molecule Types, H2 2015

Ordering:
Order Online - http://www.researchandmarkets.com/reports/3600504/
Order by Fax - using the form below
Order by Post - print the order form below and send to
Research and Markets,
Guinness Centre,
Taylors Lane,
Dublin 8,
Ireland.
Fax Order Form
To place an order via fax simply print this form, fill in the information below and fax the completed form to 646-607-1907 (from USA) or +353-1-481-1716 (from Rest of World). If you have any questions please visit http://www.researchandmarkets.com/contact/

Order Information
Please verify that the product information is correct and select the format(s) you require.

- **Product Name:** Pompe Disease - Pipeline Review, H2 2015
- **Web Address:** [http://www.researchandmarkets.com/reports/3600504/](http://www.researchandmarkets.com/reports/3600504/)
- **Office Code:** SCD2I3YY

Product Formats
Please select the product formats and quantity you require:

<table>
<thead>
<tr>
<th>Format</th>
<th>Quantity</th>
<th>Price</th>
</tr>
</thead>
<tbody>
<tr>
<td>Electronic (PDF) - Single User</td>
<td></td>
<td>USD 2000</td>
</tr>
<tr>
<td>Electronic (PDF) - Site License</td>
<td></td>
<td>USD 4000</td>
</tr>
<tr>
<td>Electronic (PDF) - Enterprisewide</td>
<td></td>
<td>USD 6000</td>
</tr>
</tbody>
</table>

Contact Information
Please enter all the information below in **BLOCK CAPITALS**

- **Title:** (Mr, Mrs, Dr, Miss, Ms, Prof)
- **First Name:**
- **Last Name:**
- **Email Address:** *
- **Job Title:**
- **Organisation:**
- **Address:**
- **City:**
- **Postal / Zip Code:**
- **Country:**
- **Phone Number:**
- **Fax Number:**

* Please refrain from using free email accounts when ordering (e.g. Yahoo, Hotmail, AOL)
Payment Information

Please indicate the payment method you would like to use by selecting the appropriate box.

☐ Pay by credit card: You will receive an email with a link to a secure webpage to enter your credit card details.

☐ Pay by check: Please post the check, accompanied by this form, to:
Research and Markets,
Guinness Center,
Taylors Lane,
Dublin 8,
Ireland.

☐ Pay by wire transfer: Please transfer funds to:
Account number 833 130 83
Sort code 98-53-30
Swift code ULSBIE2D
IBAN number IE78ULSB98533083313083
Bank Address Ulster Bank,
27-35 Main Street,
Blackrock,
Co. Dublin,
Ireland.

If you have a Marketing Code please enter it below:

Marketing Code: 

Please note that by ordering from Research and Markets you are agreeing to our Terms and Conditions at http://www.researchandmarkets.com/info/terms.asp